{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=2", "query": { "intervention": "Pemetrexed (Chemotherapy)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 381, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:09:02.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04665206", "title": "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Mesothelioma", "NSCLC" ], "interventions": [ { "name": "VT3989", "type": "DRUG" }, { "name": "Nivolumab & Ipilimumab", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Pemetrexed/Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vivace Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 434, "start_date": "2021-03-24", "completion_date": "2030-03-02", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 9, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665206" }, { "nct_id": "NCT02723955", "title": "Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "feladilimab (GSK3359609)", "type": "DRUG" }, { "name": "GSK3174998", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel plus Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine plus Carboplatin", "type": "DRUG" }, { "name": "Fluorouracil (5-FU) plus carboplatin or cisplatin", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Cobolimab", "type": "DRUG" }, { "name": "Bintrafusp alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "93 Years", "sex": "ALL", "summary": "18 Years to 93 Years" }, "enrollment_count": 829, "start_date": "2016-06-23", "completion_date": "2023-07-05", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Sarasota, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02723955" }, { "nct_id": "NCT04062708", "title": "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-03-10", "completion_date": "2027-07", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 9, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Lowell, Massachusetts + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lowell", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04062708" }, { "nct_id": "NCT06667076", "title": "A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amivantamab", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Chemotherapy: Pemetrexed", "type": "DRUG" }, { "name": "Chemotherapy: Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2024-12-16", "completion_date": "2030-12-26", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 150, "location_summary": "Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06667076" }, { "nct_id": "NCT06576635", "title": "LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2024-12-16", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06576635" }, { "nct_id": "NCT05153408", "title": "(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Respiratory Tract Neoplasms", "Neoplasms", "Neoplasms by Site", "Lung Diseases", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Adenocarcinoma", "Carcinoma", "Neoplasms by Histologic Type", "Neoplasms, Nerve Tissue", "EGFR C797S", "EGFR C797A", "EGFR L858R", "EGFR Exon 19 Deletion", "EGFR Gene Mutation", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance", "EGFR Activating Mutation", "Thoracic Neoplasms", "Antineoplastic Agents", "Protein Kinase Inhibitors", "EGFR C797G", "EGFR C797X", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "BLU-701", "type": "DRUG" }, { "name": "osimertinib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-01-13", "completion_date": "2022-12-09", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153408" }, { "nct_id": "NCT01646125", "title": "An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "AUY922", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2012-11-23", "completion_date": "2015-11-04", "has_results": true, "last_update_posted_date": "2019-07-24", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 3, "location_summary": "Los Angeles, California • Rockville, Maryland • Madison, Wisconsin", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01646125" }, { "nct_id": "NCT04267848", "title": "Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Squamous Carcinoma", "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Observation Activity", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1210, "start_date": "2020-06-16", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 1150, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04267848" }, { "nct_id": "NCT03085914", "title": "A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Investigator's choice of platinum agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-05-02", "completion_date": "2020-07-13", "has_results": true, "last_update_posted_date": "2022-09-23", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 16, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03085914" }, { "nct_id": "NCT06835569", "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC (Non-small Cell Lung Cancer)", "CRC (Colorectal Cancer)", "Advanced Solid Tumors" ], "interventions": [ { "name": "ALTA3263", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin /Carboplatin", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "GnP", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alterome Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2025-03-05", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-14T02:09:02.812Z", "location_count": 12, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06835569" } ] }